CalciMedica, Inc. (CALC) intrinsic value & 10-year financials
CalciMedica, Inc. (CALC) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.04
- Market cap
- $15.6M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -54.4%
- Free cash flow (FY2025)
- -$21.2M
CALC 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$29.6M | -$1.97 | -$21.2M | — | -595.2% |
| FY2024 | — | -$13.7M | -$1.22 | -$21.2M | — | -214.5% |
| FY2023 | — | -$34.4M | -$7.66 | -$25.8M | — | -172.6% |
| FY2022 | — | -$35.6M | -$1.66 | -$23.2M | — | -71.6% |
| FY2021 | — | -$35.8M | -$1.69 | -$32.0M | — | -44.8% |
| FY2020 | — | -$27.5M | — | -$33.1M | — | 674.1% |
| FY2019 | — | -$37.0M | — | -$31.8M | — | 43.6% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
CalciMedica, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
CalciMedica, Inc. has historically struggled to out-earn its cost of capital, averaging just -10.8% ROIC.
CalciMedica, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
CalciMedica, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.